Update Series (2019) Lesson 11: Biomarkers for Bladder Cancer Detection

NOTE: CME is no longer available for this activity.

Now in its 38th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed in consultation with and edited by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. 

Target Audience

  • Urologist
  • Resident

Learning Objectives

At the conclusion of this continuing medical education activity, the participant will understand the role of biomarkers in bladder cancer diagnosis and surveillance.

Course summary
Course opens: 
Course expires: 
List Price:

Khaled Ajib, MD
Disclosures: Nothing to disclose


Girish S. Kulkarni, MD, PhD
Disclosures: Merck, Roche, Astellas, Janssen: Advisory Board; Ferring: Paid Travel

Division of Urology
Departments of Surgery and Surgical Oncology
Princess Margaret Cancer Center
University Health Network
University of Toronto
Toronto, Canada

NOTE: CME is no longer available for this activity.

This self-study continuing medical education activity is designed to provide urologists, Board candidates and/or residents affordable and convenient access to the most recent developments and techniques in urology.
Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation: The American Urological Association designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME enduring material activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

Individual authors’ disclosures are located with their articles in each issue of The Update Series.

Update Series Advisory Group

Benjamin Newell Breyer, MD, FACSWorld Journal UrologyHealth Publishing
Sexual Medicine Open AccessHealth Publishing
Arthur Louis Burnett II, MD, MBAEndo PharmaceuticalsScientific Study or Trial
PFIZERScientific Study or Trial
National Institutes of HealthScientific Study or Trial
Auxilium IncScientific Study or Trial
American Medical Systems/Boston ScientificScientific Study or Trial
ColoplastScientific Study or Trial
Reflexonic LLCScientific Study or Trial
UMarvlConsultant or Advisor, Scientific Study or Trial
Novartis PharmaceuticalsConsultant or Advisor, Scientific Study or Trial
Futura MedicalConsultant or Advisor, Scientific Study or Trial
Acorda TherapeuticsScientific Study or Trial
Andrology (journal)Health Publishing
International Urology and Nephrology (journal)Health Publishing
AstellasConsultant or Advisor, Scientific Study or Trial
Urology Times Editorial CouncilHealth Publishing
Lilly LLCConsultant or Advisor, Scientific Study or Trial
Shelby EnglertNothing to disclose 
E. Ann Gormley, MDACGMELeadership Position
ABMSLeadership Position
AUA UpdatesLeadership Position
Cheryl Taylore Lee, MDmerckConsultant or Advisor
David Christopher Miller, MD, MPHBlue Cross Blue Shield of MichiganOther
National Cancer InstituteScientific Study or Trial
Curtis Nickel, MDFarr LaboratoriesConsultant or Advisor
AquinoxScientific Study or Trial
AUAHealth Publishing
NIHScientific Study or Trial
Canadian Institute of Health ResearchScientific Study or Trial
Alvio TherapeuticsConsultant or Advisor
Seikagaku CorporationConsultant or Advisor
RedLeaf Medical Scientific Study or Trial
TEVAConsultant or Advisor
Craig Stuart Niederberger, MDAMERICAN SOCIETY FOR REPRODUCTIVE MEDICINELeadership Position, Meeting Participant or Lecturer
NexHandLeadership Position, Investment Interest, Owner, Product Development
Ferring PharmaceuticalsScientific Study or Trial
Victor William Nitti, MDAstellasHealth Publishing, Scientific Study or Trial
AllerganHealth Publishing, Scientific Study or Trial
Serenity PharmeuticalsInvestment Interest
Cook MyositeScientific Study or Trial
MedtronicScientific Study or Trial
Mrs. Deborah F. PollyNothing to disclose 
Eila Curlee Skinner, MDGenentechScientific Study or Trial
Stacy T. Tanaka, MDAUA Update SeriesHealth Publishing
Journal of UrologyHealth Publishing
Centers for Disease Control and Prevention (CDC)Scientific Study or Trial
American Board of UrologyOther
American Academy of Pediatrics, Section on UrologyLeadership Position
J. Christian Winters, MDStimGuardConsultant or Advisor
J. Stuart Wolf Jr., MD., FACSUrology TimesHealth Publishing
University of Texas Department of Surgery & Peri-operative CareLeadership Position
American Board of UrologyLeadership Position

Off-label or Unapproved Use of Drugs or Devices: It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
Reproduction Permission: Reproduction of written materials developed for this AUA activity is prohibited without the written permission from individual authors and the American Urological Association.
Peer Review: Peer review is the principle mechanism by which the quality of the AUA Update Series content is judged by the AUA Update Series Advisory Board.

Released date: April 2019
Expiration date: April 2022


List Price:
Please login or register to take this course.